- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- NOVARTIS - MYLAN (US)
NOVARTIS vs MYLAN (US) - Comparison Results
NOVARTIS 
Change
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 NOVARTIS  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NOVARTIS Mar-18 |
MYLAN Dec-14 |
NOVARTIS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 758 | 4,097 | - | |
| Low | Rs | 579 | 2,887 | - | |
| Sales per share (Unadj.) | Rs | 228.4 | 1,402.5 | - | |
| Earnings per share (Unadj.) | Rs | 31.7 | 169.0 | - | |
| Cash flow per share (Unadj.) | Rs | 32.8 | 272.0 | - | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 297.1 | 697.2 | - | |
| Shares outstanding (eoy) | m | 24.69 | 378.37 | - | |
| Bonus/Rights/Conversions | - | OI | - | ||
| Price / Sales ratio | x | 2.9 | 2.5 | 117.6% | |
| Avg P/E ratio | x | 21.1 | 20.7 | 101.9% | |
| P/CF ratio (eoy) | x | 20.4 | 12.8 | 158.9% | |
| Price / Book Value ratio | x | 2.2 | 5.0 | 44.9% | |
| Dividend payout | % | 31.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 16,505 | 1,321,265 | 1.2% | |
| No. of employees | `000 | 0.7 | 25.0 | 2.7% | |
| Total wages/salary | Rs m | 1,445 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,441.3 | 21,226.9 | 39.8% | |
| Avg. wages/employee | Rs Th | 2,163.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,173.1 | 2,557.1 | 45.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,639 | 530,673 | 1.1% | |
| Other income | Rs m | 1,718 | -3,093 | -55.5% | |
| Total revenues | Rs m | 7,357 | 527,580 | 1.4% | |
| Gross profit | Rs m | -63 | 131,981 | -0.0% | |
| Depreciation | Rs m | 25 | 38,976 | 0.1% | |
| Interest | Rs m | 55 | 22,890 | 0.2% | |
| Profit before tax | Rs m | 1,575 | 67,022 | 2.4% | |
| Minority Interest | Rs m | 0 | -275 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 792 | 2,818 | 28.1% | |
| Profit after tax | Rs m | 784 | 63,928 | 1.2% | |
| Gross profit margin | % | -1.1 | 24.9 | -4.5% | |
| Effective tax rate | % | 50.3 | 4.2 | 1,195.1% | |
| Net profit margin | % | 13.9 | 12.0 | 115.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 9,522 | 466,532 | 2.0% | |
| Current liabilities | Rs m | 3,296 | 364,734 | 0.9% | |
| Net working cap to sales | % | 110.4 | 19.2 | 575.5% | |
| Current ratio | x | 2.9 | 1.3 | 225.8% | |
| Inventory Days | Days | 37 | 78 | 46.9% | |
| Debtors Days | Days | 28 | 107 | 26.5% | |
| Net fixed assets | Rs m | 46 | 122,770 | 0.0% | |
| Share capital | Rs m | 123 | 18,766 | 0.7% | |
| Net worth | Rs m | 7,336 | 263,797 | 2.8% | |
| Long term debt | Rs m | 0 | 394,086 | 0.0% | |
| Total assets | Rs m | 11,105 | 1,062,549 | 1.0% | |
| Interest coverage | x | 29.5 | 3.9 | 750.6% | |
| Debt to equity ratio | x | 0 | 1.5 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.5 | 101.7% | |
| Return on assets | % | 7.6 | 8.2 | 92.5% | |
| Return on equity | % | 10.7 | 24.2 | 44.1% | |
| Return on capital | % | 22.2 | 13.6 | 163.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,610 | 69,757 | 2.3% | |
| From Investments | Rs m | 687 | -55,013 | -1.2% | |
| From Financial Activity | Rs m | -2,677 | -18,381 | 14.6% | |
| Net Cashflow | Rs m | -380 | -3,636 | 10.4% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.74 Rs / USD
Compare NOVARTIS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare NOVARTIS With: TORRENT PHARMA PANACEA BIOTECH J.B.CHEMICALS SHASUN PHARMA WOCKHARDT LTD.
|
| |
Today's Market
Of IPOs, LIC-IDBI Bank Deal, and Top Cues in Focus Today(Pre-Open)
Share markets in India closed marginally higher on Friday last week. All sectoral indices traded in green, with stocks in the IT sector and stocks in the pharma sector, leading the gains.
Related Views On News
NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)
Jul 20, 2018While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.
The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)
Jul 10, 2018If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...
The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)
Jul 11, 2018The price signals that MSP sends out, creates its own set of problems.
PPF v/s Mutual Funds: Which Is Better?(Outside View)
Jul 10, 2018PersonalFN highlights the key points of distinction between PPF and mutual funds.
ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)
Jul 11, 2018PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.
More|
| |
NOVARTIS SHARE PRICE
Jul 20, 2018 (Close)
TRACK NOVARTIS
- Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NOVARTIS
NOVARTIS - TORRENT PHARMA COMPARISON
COMPARE NOVARTIS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.